Sunnybrook Health Sciences Centre, Toronto, Ontario.
Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80.
The primary objective of this guideline is to assist the practitioner in choosing an appropriate acute medication for an individual with migraine, based on current evidence in the medical literature and expert consensus. It is focused on patients with episodic migraine ( headache on ≤ 14 days a month).
A detailed search strategy was used to find a relevant meta-analyses, systematic reviews and randomized double-blind controlled trials. Recommendations were graded with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, using a consensus group. In addition, a general literature review and expert consensus were used for aspects of acute therapy for which randomized controlled trials were not available.
Twelve acute medications received a strong recommendation for use in acute migraine therapy (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zomitriptan, ASA, ibuprofen, naproxen sodium, diclofenac potassium, and acetaminophen). Four received a weak recommendation for use (dihydroergotamine, ergotamine, codeine-containing combination analgesics, and tramadol- containing medications). Three of these were NOT recommended for routine use (ergotamine and codeine- and tramadol- containing medications). Strong recommendations were made to avoid use of butorphanol and butalbital- containing medications. Metoclopramide and domperidone were strongly recommended for use when necessary. Our analysis also resulted in the formulation of eight general acute migraine management strategies. These were grouped into: 1) two mild-moderate attack strategies, 2) two moderate-severe attack or NSAID failure strategies, 3) three refractory migraine strategies, and 4) a vasoconstrictor unresponsive-contraindicated strategy. Additional were developed for menstrual migraine during pregnancy, and migraine during lactation.
This guideline provides evidence-based advice on acute pharmacological migraine therapy, and should be helpful to both health professionals and patients, The available medications have been organized into a series of strategies based on patient clinical features. These strategies may help practitioners make appropriate acute medication choices for patients with migraine.
本指南的主要目的是根据医学文献中的现有证据和专家共识,帮助医生为偏头痛患者选择合适的急性药物治疗。本指南侧重于发作性偏头痛(每月头痛≤14 天)患者。
使用详细的搜索策略来查找相关的荟萃分析、系统评价和随机双盲对照试验。使用共识小组对建议进行分级,采用推荐评估、制定与评价(GRADE)工作组的分级方法。此外,对于没有随机对照试验的急性治疗方面,还进行了一般文献综述和专家共识。
12 种急性药物被强烈推荐用于急性偏头痛治疗(阿莫曲坦、依来曲普坦、夫罗曲坦、那拉曲坦、利扎曲坦、舒马曲坦、佐米曲坦、阿司匹林、布洛芬、萘普生钠、双氯芬酸钾和对乙酰氨基酚)。4 种药物被弱推荐使用(二氢麦角胺、麦角胺、含可待因的复方镇痛药和曲马多类药物)。其中 3 种不建议常规使用(麦角胺和含可待因和曲马多的药物)。强烈建议避免使用布托啡诺和含可待因的药物。当需要时,强烈推荐使用甲氧氯普胺和多潘立酮。我们的分析还制定了八项一般的急性偏头痛管理策略。这些策略分为:1)两种轻度中度发作策略,2)两种中度重度发作或 NSAID 失败策略,3)三种难治性偏头痛策略,4)一种血管收缩剂反应不佳或禁忌策略。还制定了用于妊娠期间月经性偏头痛和哺乳期偏头痛的策略。
本指南提供了急性药物治疗偏头痛的循证建议,应该对医疗保健专业人员和患者都有帮助。现有的药物已根据患者的临床特征组织成一系列策略。这些策略可以帮助医生为偏头痛患者做出适当的急性药物选择。